微管相关蛋白在乳腺癌中的表达及作用

doi:10.3760/cma.j.issn.1673-422X.2016.10.015

摘要/Abstract

摘要： 近年来许多与乳腺癌相关的微管相关蛋白（MAP）被发现或在乳腺癌治疗中有了更深入的研究。末端结合蛋白1（EB1）蛋白能促进乳腺癌细胞的增殖，对乳腺癌具有致癌作用并影响乳腺癌治疗的化疗敏感性。含有MAP7功能域的蛋白3（Mdp3）表达在乳腺癌上皮细胞中，对其生长和转移具有重要作用。核仁纺锤体相关蛋白（NuSAP）基因在乳腺癌组织中的表达上调，可作为乳腺癌生物标志物。Tau蛋白表达水平与雌激素受体（ER）、孕激素受体（PR）及人类表皮生长因子受体2（HER2）表达水平相关，其对紫杉醇化疗和内分泌治疗患者疗效的影响仍具有较大争议性。

关键词: 微管相关蛋白质类, 乳腺肿瘤

Abstract: In recent years, many new microtubuleassociated proteins are found or studied extensively in the treatment of breast cancer. Endbinding protein 1 (EB1) has the promotional effects on cell proliferation and enhances the carcinogenesis of breast cancer, and also can affect the chemosensitivity of the treatment. MAP7 domaincontaining protein 3 (Mdp3) expresses in breast epithelial cells and plays an important role on the growth and metastasis. Nucleolar and spindleassociated protein (NuSAP) gene is upregulated in breast cancer and is considered as a biomarker for breast cancer. Tau expression level has a strong correlation with estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor2 (HER2), and it remains controversial in the results of the effect of paclitaxel chemotherapy and hormone treatment.

Key words: Microtubuleassociated proteins, Breast neoplasms

黄三钱,李晶,刘志红,曾亮. 微管相关蛋白在乳腺癌中的表达及作用[J]. 国际肿瘤学杂志, 2016, 43(10): 783-786.

Huang Sanqian, Li Jing, Liu Zhihong, Zeng Liang. Expression and role of microtubuleassociated protein in breast cancer[J]. Journal of International Oncology, 2016, 43(10): 783-786.

参考文献

［1］ Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015［J］. CA Cancer J Clin, 2016, 66(2): 115132. DOI: 10.3322/caac.21338. ［2］ Tala, Xie SB, Sun XD, et al. Microtubuleassociated protein Mdp3 promotes breast cancer growth and metastasis［J］. Theranostics, 2014, 4(10): 10521061. DOI: 10.7150/thno.9727. ［3］ Sun L, Gao J, Dong X, et al. EB1 promotes AuroraB kinase activity through blocking its inactivation by protein phosphatase 2A［J］. Proc Natl Acad Sci USA, 2008, 105(20): 71537158. DOI: 10.1073/pnas.0710018105. ［4］ Luo Y, Li D, Ran J, et al. Endbinding protein 1 stimulates paclitaxel sensitivity in breast cancer by promoting its actions toward microtubule assembly and stability［J］. Protein Cell, 2014, 5(6): 469479. DOI: 10.1007/s1323801400530. ［5］ Dong X, Liu F, Sun L, et al. Oncogenic function of microtubule endbinding protein 1 in breast cancer［J］. J Pathol, 2010, 220(3): 361369. DOI: 10.1002/path.2662. ［6］董鑫. EB1调节AuroraB活性的机制及功能［D］. 天津: 南开大学, 2011. ［7］ Thomas GE, Sreeja JS, Gireesh KK, et al. +TIP EB1 downregulates paclitaxelinduced proliferation inhibition and apoptosis in breast cancer cells through inhibition of paclitaxel binding on microtubules［J］. Int J Oncol, 2015, 46(1): 133146. DOI: 10.3892/ijo.2014.2701. ［8］ Morimura S, Takahashi K. Rac1 and Stathmin but not EB1 are required for invasion of breast cancer cells in response to IGFI［J］. Int J Cell Biol, 2011, 2011: 615912. DOI: 10.1155/2011/615912. ［9］ Sauer G, Krner R, Hanisch A, et al. Proteome analysis of the human mitotic spindle［J］. Mol Cell Proteomics, 2005, 4(1): 3543. DOI: 10.1074/mcp.M400158MCP200. ［10］ Yadav S, Verma PJ, Panda D. Cterminal region of MAP7 domain containing protein 3 (MAP7D3) promotes microtubule polymerization by binding at the Cterminal tail of tubulin［J］. PLoS One, 2014, 9(6): e99539. DOI: 10.1371/journal.pone.0099539. ［11］Tala, Sun X, Chen J, et al. Microtubule stabilization by Mdp3 is partially attributed to its modulation of HDAC6 in addition to its association with tubulin and microtubules［J］. PLoS One, 2014, 9(3): e90932. DOI: 10.1371/journal.pone.0090932. eCollection 2014. ［12］Gallaud E, Caous R, Pascal A, et al. Ensconsin/map7 promotes microtubule growth and centrosome separation in drosophila neural stem cells ［J］. J Cell Biol, 2014, 204(7): 11111121. DOI: 10.1083/jcb.201311094. ［13］Cassimeris L, Spittle C. Regulation of microtubuleassociated proteins ［J］. Int Rev Cytol, 2001, 210: 163226. ［14］Raemaekers T, Ribbeck K, Beaudouin J, et al. NuSAP, a novel microtubuleassociated protein involved in mitotic spindle organization［J］. J Cell Biol, 2003, 162(6): 10171029. DOI: 10.1083/jcb.200302129. ［15］Vanden Bosch A, Raemaekers T, Denayer S, et al. NuSAP is essential for chromatininduced spindle formation during early embryogenesis［J］. J Cell Sci, 2010, 123(Pt 19): 32443255. DOI: 10.1242/jcs.063875. ［16］Davis JN, Wojno KJ, Daignault S, et al. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormoneresistant prostate cancer［J］. Cancer Res, 2006, 66(24): 1189711906. ［17］Gulzar ZG, Mckenney JK, Brooks JD. Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1［J］. Oncogene, 2013, 32(1): 7077. DOI: 10.1038/onc.2012.27. ［18］Kretschmer C, SternerKock A, Siedentopf F, et al. Identification of early molecular markers for breast cancer［J］. Mol Cancer, 2011, 10(1): 15. DOI: 10.1186/147645981015. ［19］ Chen DT, Nasir A, Culhane A, et al. Proliferative genes dominate malignancyrisk gene signature in histologicallynormal breast tissue［J］. Breast Cancer Res Treat, 2010, 119(2): 335346. DOI: 10.1007/s105490090344y. ［20］何敢, 喻嫦娥, 吴海滨, 等. NuSAP在乳腺癌中的表达及临床意义［J］. 中国普通外科杂志, 2015, 24(5): 707711. DOI: 10.3978/j.issn.10056947.2015.05.018. ［21］ Bonneau C, GurardLevin ZA, Andre F, et al. Predictive and prognostic value of the Tau protein in breast cancer［J］. Anticancer Res, 2015, 35(10): 51795184. ［22］ Andre F, Hatzis C, Anderson K, et al. Microtubule associated proteintau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptorpositive breast cancer［J］. Clin Cancer Res, 2007, 13(7): 20612067. ［23］范小庆, 熊秋云, 涂剑宏, 等. 乳腺浸润性导管癌组织中Tau蛋白表达及其与临床病理因素相关性分析［J］. 中华医学杂志, 2013, 93(16): 12581260. DOI: 10.3760/cma.j.issn.03762491.2013.16.013. ［24］ Honig A, Gehrmann M, Kranke P, et al. Microtubuleassociated protein tau correlates with estrogen receptor status but not with in vitro paclitaxel sensitivity in primary breast cancer［J］. Eur J Gynaecol Oncol, 2014, 35(5): 503507. ［25］ Koo DH, Lee HJ, Ahn JH, et al. Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2positive breast cancer［J］. Tumour Biol, 2015, 36(8): 58655871. DOI: 10.1007/s1327701532589. ［26］ Wang K, Deng QT, Liao N, et al. Tau expression correlated with breast cancer sensitivity to taxanesbased neoadjuvant chemotherapy［J］. Tumour Biol, 2013, 34(1): 3338. DOI: 10.1007/s132770120507z. ［27］ Zhou J, Qian S, Li H, et al. Predictive value of microtubuleassociated protein Tau in patients with recurrent and metastatic breast cancer treated with taxanecontaining palliative chemotherapy［J］. Tumour Biol, 2015, 36(5): 39413947. DOI: 10.1007/s1327701530377. ［28］ Won HS, Lee KE, Sung SH, et al. Topoisomerase Ⅱ alpha and microtubuleassociated proteintau as a predictive marker in axillary lymph node positive breast cancer［J］. Tumori, 2014, 100(1): 8086. DOI: 10.1700/1430.15820. ［29］ Irshad S, Gillett C, Pinder SE, et al. Assessment of microtubuleassociated protein (MAP)Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer［J］. Breast Cancer Res Treat, 2014, 144(2): 331341. DOI: 10.1007/s1054901428554.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[5]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[6]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[7]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[8]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[9]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[10]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[12]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[13]	黎立喜, 张娣, 罗扬, 马飞. PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.
[14]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦. 伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.
[15]	耿睿, 马俊强, 郭强, 牛钊峰. 老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.